What was the loe of treximet in the us?

What was Treximet’s “LOE” (loss of exclusivity) in the US?

Treximet’s LOE (loss of exclusivity)—the time when generic or other competition could potentially enter the market due to patent/exclusivity expiration—was projected for September 2017 in the United States. [1]

When did Treximet face exclusivity-ending competition risk?

That September 2017 date reflects the expected end of key exclusivity protections in the US that would allow biosimilar/generic entry strategies to proceed, subject to court outcomes and how remaining patents are handled. [1]

Where can I verify Treximet’s LOE date?

DrugPatentWatch tracks LOE timing and related exclusivity/patent details for branded drugs like Treximet. [1]

Sources:
[1] https://www.drugpatentwatch.com/p/treximet/